Skip to main content
Atrás
Watch Compare

NeuroSense Therapeutics Ltd.

Calidad de datos: 83%
También listada como NRSNW NASDAQ
NRSN
NASDAQ Manufacturing Chemicals
$0.72
▲ $0.01 (1.28%)
Cap. Mercado: 23.74 M
6 months return
—
Momentum
Neutral
Free cash flow
-7.68 M

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -7.68 M

Price History

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio0.71
Interest CoverageN/A

Valoración

PE (TTM|NTM)
-2.13 | -1.39
Below sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1605 pares)
Métrica Acción Mediana del Sector
P/E -2.1 -1.5
P/B — 1.6
ROE % — -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

4 analistas

Consenso de analistas: objetivo medio vs precio actual y calificación.

Buy
Actual
$0.72
+1063.4%
Objetivo
$8.38
$3.00
$8.25
$14.00
Pronóstico
P/E Futuro -1.39
EPS Futuro -$0.51
Ingresos Est. 4.88 M

Estimaciones de Ganancias

Pronósticos de EPS e ingresos por período. Anual = años fiscales; trimestral = próximos trimestres.

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.51
-$0.82 – -$0.19
4.88 M 2
FY2026 -$0.31
-$0.40 – -$0.21
714,000.0 2

Sorpresas de Ganancias

Últimos 3 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.04 — —
Q32025 -$0.04 — —
Q22025 -$0.37 — —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -11.13 M
ROE N/A ROA -631.21%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -7.68 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.71
Interest Coverage N/A Asset Turnover N/A
Working Capital -647,000 Tangible Book Value -519,000
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.13 Forward P/E -1.39
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 4.86 Fwd Earnings Yield N/A
FCF Yield -32.34%
Market Cap 23.74 M Enterprise Value 23.08 M
Per Share
EPS (Diluted TTM) -0.44 Revenue / Share N/A
FCF / Share -0.23 OCF / Share -0.23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 69.02%
SBC-Adj. FCF -9.82 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2023 FY2024
Revenue — — —
Net Income -11.13 M -10.11 M -10.21 M
EPS (Diluted) -0.44 -0.74 -0.54
Gross Profit — — —
Operating Income -11.09 M -12.05 M -9.90 M
EBITDA — — —
R&D Expenses 6.23 M 7.27 M 5.70 M
SG&A Expenses — — —
D&A — — —
Interest Expense — — —
Income Tax — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2023 FY2024
Total Assets 1.03 M 3.19 M 4.58 M
Total Liabilities 2.59 M 4.94 M 1.99 M
Shareholders' Equity -1.56 M -1.76 M 2.58 M
Total Debt — — —
Cash & Equivalents 166,000.0 2.64 M 3.38 M
Current Assets 778,000.0 2.92 M 4.40 M
Current Liabilities 2.52 M 3.46 M 1.99 M